Xeljanz Lawsuit 2026: Blood Clots, Heart Attacks & the FDA Black Box Warning — Who Can Still File

Lawsuits against Pfizer allege Xeljanz (tofacitinib) caused blood clots, heart attacks, strokes, cancer, and deaths that earlier warnings might have prevented. In September 2021 the FDA imposed its strongest warning on the drug. Unlike most drug litigations, there is no MDL or class action — cases proceed individually.

Key Facts

  • On September 1, 2021, the FDA required a boxed warning — its most prominent warning — on Xeljanz for increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death, based on the completed ORAL Surveillance trial.
  • ORAL Surveillance, Pfizer's FDA-mandated postmarketing trial, enrolled more than 4,600 rheumatoid arthritis patients aged 50 or older with at least one cardiovascular risk factor and compared tofacitinib against a TNF blocker. Patients on tofacitinib had roughly 50% more new malignancies and about one-third more major cardiovascular events.
  • In February 2019, the FDA warned that the highest recommended Xeljanz dose — 10 mg twice daily — raised the risk of pulmonary embolism (a blood clot in the lungs) and death.
  • There is no Xeljanz MDL and no class action, per the JPML's pending-MDL list dated March 2, 2026. The one reported federal case, Stube v. Pfizer, ended July 14, 2020 with a joint dismissal — no public settlement terms, no payout fund, no group case for new claimants to join.

What Xeljanz Is — and Why It Raised Alarms

Xeljanz is the brand name for tofacitinib, a Janus kinase (JAK) inhibitor — a drug that blocks part of the immune system's inflammatory signaling. It was approved by the FDA in 2012 for rheumatoid arthritis and later for psoriatic arthritis and ulcerative colitis. The standard tablets come in 5 mg and 10 mg doses taken twice daily; Xeljanz XR is an 11 mg extended-release tablet taken once daily.

The paradox at the heart of every lawsuit: a medicine designed to calm inflammation appeared, in a large randomized trial, to raise the odds of the deadliest outcomes. Rheumatoid arthritis patients already carry elevated cardiovascular risk — which is exactly why the FDA ordered the safety trial.

The FDA's Escalating Warnings

The regulatory story unfolded in three acts. In February 2019, the FDA issued a safety warning that the 10 mg twice-daily dose — then the highest recommended — was associated with an increased risk of pulmonary embolism and death, based on interim trial data.

The decisive act came on September 1, 2021, when the FDA's Drug Safety Communication announced its final review of ORAL Surveillance and required a boxed warning for Xeljanz covering serious heart-related events such as heart attack or stroke, cancer, blood clots, and death. Because Olumiant (baricitinib) and Rinvoq (upadacitinib) share the same mechanism, the agency extended heightened warnings to them too, even though they had not been studied in a trial of that scale.

A year later, the European Medicines Agency recommended restricting JAK inhibitors to patients with no suitable alternative — those 65 and older, long-time smokers, or people at elevated cardiovascular or cancer risk.

What the Lawsuits Allege

The core claim in Xeljanz suits is failure to warn: that Pfizer knew — or should have known — about the cardiovascular, clotting, and cancer risks and did not adequately communicate them to doctors or patients in time. Some complaints also raise defective-design and misrepresentation theories, though in the one fully litigated federal case a judge dismissed the fraud and negligent-misrepresentation claims while letting the failure-to-warn claims proceed.

The injuries at issue track the boxed warning exactly: blood clots including deep vein thrombosis and pulmonary embolism, heart attack, stroke, cancers — particularly lung cancer and lymphoma — serious infections, and death. The FDA's adverse-event database has received more than 100 reports of pulmonary embolism on Xeljanz, with more than a dozen deaths, plus dozens of deep-vein-thrombosis reports — reports, not verdicts, but part of why lawyers keep reviewing these files.

What the Courts Have Actually Done

Here honesty matters more than hype. As of 2026, there is no multidistrict litigation for Xeljanz and no certified class action. Lawsuits are proceeding individually in the courts where they were filed — a slower, quieter path than the blockbuster MDLs of Roundup or talc.

The most fully documented federal case was Stube v. Pfizer. In March 2020, the judge dismissed the fraud and negligent-misrepresentation claims without prejudice — and rejected the theory that Pfizer had to warn the patient directly rather than her physicians — but every other claim, including the central failure-to-warn claim, survived. That July, both sides filed a joint dismissal described as a settlement order. No terms were ever made public.

The takeaway is plain: there is no public Xeljanz settlement fund, no court-approved payout schedule, and no ongoing group case a new claimant could join. Anyone telling you otherwise is not describing the current record.

Who May Still Qualify

Lawyers reviewing Xeljanz cases generally look for three things. First, a prescription history: Xeljanz, Xeljanz XR, or the oral solution prescribed for rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis. Second, a qualifying injury after starting the drug: a blood clot, heart attack, stroke, cancer diagnosis, or the death of a loved one. Third, timing that fits the window the ORAL Surveillance trial examined.

The evidence that strengthens a file is mundane but decisive: pharmacy records showing the drug, dose, and dates; medical records documenting the diagnosis being treated and the later injury; and any correspondence with the prescribing doctor about Xeljanz and its risks. Keep everything. Drug-injury cases are built on paper trails, not memories.

Deadlines and What to Do Next

There is no federal deadline — the clock comes from state law, and it varies. Many states run it from when you knew, or should have known, the drug was linked to your injury, but some windows are unforgivingly short. The September 2021 boxed warning is exactly the kind of public event defense lawyers will argue put patients on notice.

If you are considering a claim: gather the paper trail (pharmacy records, medical records for both the condition treated and the injury suffered); write a dated timeline; and have a drug-litigation attorney review the file — these cases are almost always taken on contingency. For context, see the Abilify litigation, the Invokana litigation, and how product-liability lawyers evaluate cases.

For plain-English explainers on lawsuits and money topics, watch Problem Solved on YouTube.

Who Benefits From This — and Who Does Not

Who benefits most from this guide:

Patients prescribed Xeljanz, Xeljanz XR, or the oral solution for rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis who then suffered a blood clot, heart attack, stroke, cancer diagnosis, or the death of a loved one. How: lawyers look for prescription history, a qualifying injury after starting the drug, and timing that fits the warnings.

Patients whose injury followed the September 1, 2021 boxed warning. How: the FDA required its most prominent warning for serious heart-related events, cancer, blood clots, and death based on the ORAL Surveillance trial.

People who kept prescription and treatment records. How: the prescription history and the injury timeline are the first things a reviewing lawyer checks.

Who does not benefit:

Anyone who took Xeljanz without a qualifying injury. How: these cases require an injury after starting the drug, not use of the drug alone.

Anyone expecting to join a class action or multidistrict litigation. How: there is no Xeljanz MDL and no class action, per the JPML pending-MDL list dated March 2, 2026, so cases proceed individually.

Anyone planning to stop the drug on their own because of the warnings. How: the FDA cautions patients not to stop taking Xeljanz without talking to their doctor first, since stopping can also cause harm.

A similar individual-filing landscape, with no pending federal MDL, is covered in our guide to the Invokana lawsuit, where new claims must also be filed individually.

Frequently Asked Questions

Is there a Xeljanz class action lawsuit in 2026?

No. There is no Xeljanz MDL and no certified class action; individual lawsuits are proceeding in the courts where they were filed. No group case currently exists for new claimants to join.

What is the FDA boxed warning on Xeljanz?

On September 1, 2021, the FDA required its most prominent warning on Xeljanz for increased risk of serious heart-related events such as heart attack or stroke, cancer, blood clots, and death, based on the completed ORAL Surveillance trial of more than 4,600 patients.

Has Pfizer settled any Xeljanz lawsuits?

There is no public Xeljanz settlement fund and no announced payout schedule. The one reported federal case, Stube v. Pfizer, ended July 14, 2020 with a joint dismissal described as a settlement order — but no terms were ever made public.

Should I stop taking Xeljanz because of the warnings?

The FDA cautions patients not to stop taking Xeljanz without talking to their doctor first, since stopping can also cause harm. Discuss the boxed warning with your prescribing physician.

Who can still file a Xeljanz lawsuit?

Patients prescribed Xeljanz for rheumatoid arthritis, psoriatic arthritis, or ulcerative colitis who suffered a blood clot, heart attack, stroke, cancer, or the death of a loved one after starting the drug can still have an individual case evaluated, since there is no MDL or class action to join.

Who cannot file a Xeljanz claim?

People who took Xeljanz but suffered no qualifying injury cannot file, and neither can anyone expecting a group settlement, because there is no public Xeljanz settlement fund and no announced payout schedule.

Disclaimer: This article is general information, not legal or medical advice. Drug claims have strict deadlines that vary by state; speak with a licensed attorney about your situation before relying on any of it, and consult your doctor about any medication decision.

Watch on YouTube

Problem Solved on YouTube